References
This site is based on studies published in peer-reviewed medical journals and on guidelines from national and international medical societies. No clinical claim here is invented — each one can be checked at the original source.
1. Semaglutide (Ozempic/Wegovy) — efficacy and treatment profile
Wilding JPH, Batterham RL, Calanna S, et al., for the STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384:989-1002.
View original source2. Tirzepatide (Mounjaro/Zepbound) — efficacy and treatment profile
Jastreboff AM, Aronne LJ, Ahmad NN, et al., for the SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387:205-216.
View original source3. Lean mass loss during GLP-1 treatment — systematic review
Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: systematic review and network meta-analysis. Metabolism. 2024.
View original source4. Hair loss (telogen effluvium) associated with weight loss
Telogen Effluvium Associated With Weight Loss: A Single Center Retrospective Study. Ann Dermatol. 2024.
View original source5. Strength training and protein for preserving muscle mass
Nutritional and exercise interventions in individuals with sarcopenic obesity around retirement age: a systematic review and meta-analysis. 2023.
View original source6. Protein and exercise recommendations in sarcopenic obesity
Exercise and Protein Supplementation Recommendations for Older Adults With Sarcopenic Obesity: A Meta-Review. 2023.
View original source7. Brazilian position statement on pharmacologic obesity treatment
Pharmacologic Treatment of Obesity in Adults and Its Impact on Comorbidities: 2024 Update and Position Statement of Specialists from ABESO and SBEM.
View original source8. Brazilian obesity guidelines (official portal)
Associação Brasileira para o Estudo da Obesidade e da Síndrome Metabólica (ABESO). Diretrizes.
View original source